Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis

Recruiting now

Conditions studied: Endometrial Cancer

In brief

Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in a personalized manner. However, there are no studies on EC molecular classification in Mexican women or its impact on prognosis and the possible modification of targeted treatment. The investigators will determine the molecular classification in EC by next-generation sequencing (NGS) to detect TP53 and POLE somatic mutations, and immunohistochemical detection of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3) in a cohort of patients with endometrioid-type EC, endometrioid subtype, attended at the Instituto Nacional de Cancerología - Mexico (INCan) and determine its impact on clinical prognosis.

Key facts

Study ID

NCT06206083

Run by

National Institute of Cancerología

People needed

64

Starts

2024-03-01

Expected to finish

2027-02-01

Last updated by the study team

2024-02-28

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may not qualify if…

• Samples with CEE of non-endometroid type.
• Samples from patients with double primary neoplasm, including carcinoma ductal in situ, squamous cell skin cancers, and cervical carcinoma in situ
• History of malignancy < 5 years prior with no evidence of disease (i.e., remission).

Where it is running

• Instituto Nacional de Cancerología — Mexico City, Mexico City, Mexico (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.